Drugs / rDEN4delta30-4995
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00322946 | Jan 2007 → Aug 2009 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN4delta30-4995 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00322946 ↗ |
| Modality | Vaccine | “a live attenuated recombinant virus derived from rDEN4delta30 for protection against dengue virus serotype 4” NCT00322946 ↗ |
| Route | Subcutaneous | “One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10\^5 PFU dose) into the deltoid region of either arm.” NCT00322946 ↗ |